Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
about
Rituximab for treating inhibitors in people with inherited severe hemophiliaTreatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryRituximab for treating inhibitors in children with hemophiliaPotential role of a new PEGylated recombinant factor VIII for hemophilia A.Switching treatments in haemophilia: is there a risk of inhibitor development?FVIII inhibitors: pathogenesis and avoidanceReversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015Different impact of factor VIII products on inhibitor development?Aspects of prophylactic treatment of hemophiliaLarge scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.The current state of adverse event reporting in hemophilia.Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXCurrent and evolving features in the clinical management of haemophiliaDesign of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.A public health approach to the prevention of inhibitors in hemophilia.Factor VIII gene variants and inhibitor risk in African American hemophilia A patientsAchievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.Key issues in inhibitor management in patients with haemophilia.Italian Registry of Congenital Bleeding Disorders.Considerations in individualizing prophylaxis in patients with haemophilia A.Factor VIII therapy for hemophilia A: current and future issues.Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.Inhibitors - genetic and environmental factors.Joint WFH-ISTH session: issues in clinical trial design.The role of Rixubis™ in the treatment of hemophilia B.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Non-genetic risk factors and their influence on the management of patients in the clinic.Strategies for reducing inhibitor formation in severe haemophilia.The growing number of hemophilia registries: Quantity vs. quality.The current status of prophylactic replacement therapy in children and adults with haemophilia.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.The role of previously untreated patient studies in understanding the development of FVIII inhibitors.Engineering less immunogenic and antigenic FVIII proteins.Rituximab for treating inhibitors in people with inherited severe hemophilia.Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor.Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidence.Safety surveillance in haemophilia and allied disorders.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.
P2860
Q24186623-2956ED2F-9B7A-4106-8C2D-9A60AEB3CC9AQ24188177-64C1829F-7497-4CB9-B46C-DB2FB53FBFF6Q24197700-288BDFF8-7FBD-42A2-B757-9A19ED646B25Q26744309-D12B4029-C132-45C3-B27C-9B3A39650146Q27001016-E11DCE20-34E4-475C-950F-230942DA4E18Q27027224-BE2FB88F-8AE4-4B0B-9EA2-71C6FAC7D455Q28072261-8DBAAEC6-8704-42DD-8304-C0FEA4DB7789Q28075679-0EA44E52-AFD3-4759-9FFE-2125F11D06F4Q28078562-1214A094-41C0-4B7D-955E-4FB798E7B0FCQ30234910-21FED92D-DEAA-4732-A507-26ECFC1E0121Q30239952-E0E3684D-23CB-4D41-8122-D5E8D09C6595Q33608230-D0DD3E8A-3308-461A-8DD2-3205C2B0C0FBQ33708976-07D63569-1953-46EC-BD91-AC46F5ACEA0CQ35168244-7F4E5332-1AEB-45D9-B1AA-BDE0A5B87E81Q35747998-0E0F3F62-0AEA-4E9D-9BA2-07B5FD719BF0Q35953537-7267D15A-24DC-4E3B-AAC1-302F09D5F9F4Q37185097-56CBAA3E-8651-45F7-B2F9-3BF27FC20840Q37381565-12DD66D2-6D09-4E95-8CBA-B0A8DA5227D2Q37602415-44D83E52-688F-4378-B33B-72379D34913EQ37729949-6DFCEF54-53A0-4715-9011-C2DC0EC70F42Q38203021-9E4BF3C9-B598-41D8-829F-70E30368B349Q38203350-24A3603F-C1AC-4367-B09E-1890E41BA4B1Q38206855-7A09D696-DF8A-460A-ABAE-3FE2DE1669C1Q38206856-4CD142BE-113C-44F5-A8B2-69688DBAE9F8Q38206863-BB7A2473-47FA-4CB9-AC67-59AF9F3F7B1CQ38210808-A3A6E41A-A2DB-4EC1-BE6D-D9E080F6B9ABQ38227605-6C663450-CEB8-4149-A1E1-739F6210F229Q38308194-6E87F75E-5EFB-4B91-995B-32B61E005908Q38308222-1A7DCE5E-5D6B-4B93-8823-06F67BC55C58Q38351067-A1CA0993-7760-4D56-9922-7CED5B055479Q38394904-2341FF86-9A3B-413B-9875-80C6956C22A3Q38574414-1DFB84BD-E1E9-46C7-8C9A-A27933C9614FQ38575475-8BE749A8-3B9C-4260-852A-BBF51A71EC68Q38632876-AC9856BF-5F35-4EEF-8E75-30E6366A93A2Q38661525-2FCADBFA-9A1F-430E-9CB0-64DE6A493C2BQ38691244-747E83A8-D683-4E10-B0AD-EC99A0D1CE45Q38722283-0E6CEA26-CAF6-4157-B60D-8D54F5BF7856Q38783210-FCBF2CAC-928C-4110-897E-0F07B1D6C1BBQ38784133-23724893-E2FA-4AF2-83F1-86A4A00F0B17Q38828174-83F62E1E-6BBE-4357-9380-6AE618208CBD
P2860
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Intensity of factor VIII treat ...... hemophilia A: the RODIN study.
@en
Intensity of factor VIII treat ...... hemophilia A: the RODIN study.
@nl
type
label
Intensity of factor VIII treat ...... hemophilia A: the RODIN study.
@en
Intensity of factor VIII treat ...... hemophilia A: the RODIN study.
@nl
prefLabel
Intensity of factor VIII treat ...... hemophilia A: the RODIN study.
@en
Intensity of factor VIII treat ...... hemophilia A: the RODIN study.
@nl
P2093
P921
P1433
P1476
Intensity of factor VIII treat ...... hemophilia A: the RODIN study.
@en
P2093
Anne Rafowicz
Beatrice Nolan
Carmen Altisent
Elizabeth Chalmers
Günter Auerswald
H Marijke van den Berg
Helen Platokouki
Hervé Chambost
Johannes Oldenburg
Karin Kurnik
P304
P356
10.1182/BLOOD-2012-09-457036
P407
P577
2013-04-03T00:00:00Z